{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:33:06Z","timestamp":1790209986147,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ObvioHealth"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pre-existing cardiometabolic comorbidities place SARS-CoV-2 positive patients at a greater risk for poorer clinical course and mortality than those without it. We aimed to analyze real-world registry data focused primarily on participants with cardiometabolic diseases (CMD), which were remotely obtained via a digital platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were divided into two groups: CMD or no cardiometabolic disease (non-CMD). They were evaluated based on their medical history, current medications\/supplements, COVID-19 status, demographics, and baseline characteristics. The frequency of medications\/supplements for CMD were compared using relative risks and 95% confidence intervals. The WHO (Five) Well-Being Index (WHO-5) were collected monthly for 6\u00a0months to assess psychological well-being which included cheerfulness, calmness, vigor, rest, and engagement with daily activities of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 791 enrollees represented 49 U.S. states. The CMD group had significantly higher (p\u2009&lt;\u20090.0001) BMI (mean\u2009+\u20093.04\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and age (mean\u2009+\u20099.15\u00a0years) compared to non-CMD group. In the CMD group, participants who tested positive for COVID-19 had lower (p\u2009&lt;\u20090.0001) well-being scores than those without COVID-19. For the 274 participants on CMD medications\/supplements, there was no statistical difference in risk of COVID-19 contracture based on medication\/supplement type; however, all six participants who were not being treated for CMD were COVID-19 positive (RR ~\u2009104). For 89 participants who were on treatment for diabetes or insulin resistance, there was a 90% reduced risk of COVID-19 incidence (p\u2009=\u20090.0187).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The well-being score of the CMD group was dependent on whether they tested positive for COVID-19. Type of CMD treatment did not impact COVID-19 status, but absence of treatment significantly increased COVID-19 incidence. With respect to SARS-CoV-2, our analysis supports continued use of the statins, ACE-I, ARBs, and diabetes medications in CMD patients.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      : ClinicalTrials.gov Identifier: NCT04348942.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01462-3","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T09:03:12Z","timestamp":1644829392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real world data on cardiometabolic diseases in U.S. adults during the SARS-CoV-2 pandemic: a decentralized registry study"],"prefix":"10.1186","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct04348942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Parth","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara H.","family":"Buccellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna","family":"Ismond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalisa","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-48382-5_1","volume":"960","author":"A Engin","year":"2017","unstructured":"Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1\u201317.","journal-title":"Adv Exp Med Biol"},{"key":"1462_CR2","unstructured":"CDC. Prediabetes\u2014your chance to prevent type 2 diabetes. Centers for Disease Control and Prevention. 2020."},{"key":"1462_CR3","unstructured":"CDC. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention. 2020."},{"issue":"18","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2021.5469","volume":"325","author":"FB Ahmad","year":"2021","unstructured":"Ahmad FB, Anderson RN. The leading causes of death in the US for 2020. JAMA. 2021;325(18):1829\u201330.","journal-title":"JAMA"},{"issue":"9","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2337\/dbi19-0023","volume":"69","author":"F Mauvais-Jarvis","year":"2020","unstructured":"Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes. 2020;69(9):1857\u201363.","journal-title":"Diabetes"},{"issue":"4","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cid\/ciaa815","volume":"72","author":"DBG Tai","year":"2020","unstructured":"Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. Clin Infect Dis. 2020;72(4):703\u20136.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1462_CR7","first-page":"243","volume":"17","author":"ZH Sun","year":"2020","unstructured":"Sun ZH. Clinical outcomes of COVID-19 in elderly male patients. J Geriatr Cardiol. 2020;17(5):243\u20135.","journal-title":"J Geriatr Cardiol"},{"issue":"7837","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315\u201320.","journal-title":"Nature"},{"issue":"12","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","volume":"13","author":"H Ejaz","year":"2020","unstructured":"Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833\u20139.","journal-title":"J Infect Public Health"},{"key":"1462_CR10","doi-asserted-by":"publisher","first-page":"173899","DOI":"10.1016\/j.ejphar.2021.173899","volume":"896","author":"R Parit","year":"2021","unstructured":"Parit R, Jayavel S. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study. Eur J Pharmacol. 2021;896:173899.","journal-title":"Eur J Pharmacol."},{"key":"1462_CR11","doi-asserted-by":"publisher","first-page":"154373","DOI":"10.1016\/j.metabol.2020.154373","volume":"117","author":"Y Du","year":"2021","unstructured":"Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2021;117:154373.","journal-title":"Metabolism"},{"issue":"6515","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.abe2813","volume":"370","author":"EJ Topol","year":"2020","unstructured":"Topol EJ. COVID-19 can affect the heart. Science. 2020;370(6515):408\u20139.","journal-title":"Science"},{"issue":"1","key":"1462_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/STROKEAHA.117.019395","volume":"49","author":"S Yaghi","year":"2018","unstructured":"Yaghi S, Chang AD, Ricci BA, Jayaraman MV, McTaggart RA, Hemendinger M, et al. Early elevated troponin levels after ischemic stroke suggests a cardioembolic source. Stroke. 2018;49(1):121\u20136.","journal-title":"Stroke"},{"issue":"24","key":"1462_CR14","doi-asserted-by":"publisher","first-page":"e3373","DOI":"10.1212\/WNL.0000000000010851","volume":"95","author":"S Fridman","year":"2020","unstructured":"Fridman S, Bres Bullrich M, Jimenez-Ruiz A, Costantini P, Shah P, Just C, et al. Stroke risk, phenotypes, and death in COVID-19: systematic review and newly reported cases. Neurology. 2020;95(24):e3373\u201385.","journal-title":"Neurology"},{"issue":"3","key":"1462_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.dsx.2020.03.013","volume":"14","author":"M Bansal","year":"2020","unstructured":"Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247\u201350.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1462_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11239-020-02224-2","volume":"51","author":"F Du","year":"2021","unstructured":"Du F, Liu B, Zhang S. COVID-19: the role of excessive cytokine release and potential ACE2 down-regulation in promoting hypercoagulable state associated with severe illness. J Thromb Thrombolysis. 2021;51(2):313\u201329.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"1462_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/17474086.2020.1831383","volume":"13","author":"M Rostami","year":"2020","unstructured":"Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020;13(11):1265\u201375.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"1462_CR18","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.jdiacomp.2021.107927","volume":"35","author":"A Ceriello","year":"2021","unstructured":"Ceriello A, Prattichizzo F. Pharmacological management of COVID-19 in type 2 diabetes. J Diabetes Complications. 2021;35(7):107927.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"1462_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12933-021-01368-6","volume":"20","author":"JM Rivera-Caravaca","year":"2021","unstructured":"Rivera-Caravaca JM, Harrison SL, Buckley BJR, Fazio-Eynullayeva E, Underhill P, Marin F, et al. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. Cardiovasc Diabetol. 2021;20(1):176.","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"1462_CR20","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1462_CR21","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","volume":"318","author":"AM South","year":"2020","unstructured":"South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084\u201390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"1462_CR22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/jmv.26625","volume":"93","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, et al. The use of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2021;93(3):1370\u20137.","journal-title":"J Med Virol"},{"issue":"3","key":"1462_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","volume":"84","author":"CW Topp","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P. The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167\u201376.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"1462_CR24","doi-asserted-by":"publisher","first-page":"H296","DOI":"10.1152\/ajpheart.00755.2020","volume":"320","author":"A Viveiros","year":"2021","unstructured":"Viveiros A, Rasmuson J, Vu J, Mulvagh SL, Yip CYY, Norris CM, et al. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. Am J Physiol Heart Circ Physiol. 2021;320(1):H296-h304.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"1462_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442\u20137.","journal-title":"Nat Rev Immunol"},{"key":"1462_CR26","doi-asserted-by":"publisher","first-page":"600439","DOI":"10.3389\/fendo.2020.600439","volume":"11","author":"A Crouse","year":"2020","unstructured":"Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne). 2021;11:600439. https:\/\/doi.org\/10.3389\/fendo.2020.600439.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1462_CR27","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/jmv.25889","volume":"92","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(10):1915\u201321.","journal-title":"J Med Virol"},{"key":"1462_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2021.03.004","author":"SM Samuel","year":"2021","unstructured":"Samuel SM, Varghese E, B\u00fcsselberg D. Therapeutic potential of metformin in COVID-19: reasoning for its protective role. Trends Microbiol. 2021. https:\/\/doi.org\/10.1016\/j.tim.2021.03.004.","journal-title":"Trends Microbiol"},{"issue":"5","key":"1462_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.pcd.2021.08.001","volume":"15","author":"A Elibol","year":"2021","unstructured":"Elibol A, Eren D, Erdogan MD, Elmaagac M, Dizdar OS, Celik I, et al. Factors influencing on development of COVID-19 pneumonia and association with oral anti-diabetic drugs in hospitalized patients with diabetes mellitus. Prim Care Diabetes. 2021;15(5):806\u201312.","journal-title":"Prim Care Diabetes"},{"issue":"4","key":"1462_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11154-020-09569-2","volume":"21","author":"M Marazuela","year":"2020","unstructured":"Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord. 2020;21(4):495\u2013507.","journal-title":"Rev Endocr Metab Disord"},{"key":"1462_CR31","first-page":"3076463","volume":"2020","author":"Z Li","year":"2020","unstructured":"Li Z, Cheng Y, Wang D, Chen H, Chen H, Ming W-k, et al. Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women. J Diabetes Res. 2020;2020:3076463.","journal-title":"J Diabetes Res"},{"issue":"4","key":"1462_CR32","first-page":"1","volume":"2","author":"P Shah","year":"2018","unstructured":"Shah P. The role of vitamin D in gestational diabetes mellitus and its therapeutic implications. CPQ Med. 2018;2(4):1\u20135.","journal-title":"CPQ Med."},{"key":"1462_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1966","author":"CM Petrilli","year":"2020","unstructured":"Petrilli CM, Jones SA, Yang J, Rajagopalan H, O\u2019Donnell L, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m1966.","journal-title":"BMJ"},{"issue":"7","key":"1462_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/oby.22831","volume":"28","author":"A Simonnet","year":"2020","unstructured":"Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28(7):1195\u20139.","journal-title":"Obesity"},{"issue":"7","key":"1462_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41574-020-0364-6","volume":"16","author":"N Stefan","year":"2020","unstructured":"Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341\u20132.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"1462_CR36","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ajem.2020.04.048","volume":"38","author":"B Long","year":"2020","unstructured":"Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504\u20137.","journal-title":"Am J Emerg Med"},{"key":"1462_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315551","author":"H-Y Lee","year":"2021","unstructured":"Lee H-Y, Ahn J, Park J, Kyungang C, Won S-H, Wookim D, et al. Beneficial effect of statins in COVID-19\u2013related outcomes\u2014brief report. Arterioscler Thromb Vasc Biol. 2021. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315551.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"1462_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1055\/s-0040-1722307","volume":"47","author":"M Pucci","year":"2021","unstructured":"Pucci M, Onorato D, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost. 2021;47(04):392\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"1462_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12933-021-01336-0","volume":"20","author":"P Lohia","year":"2021","unstructured":"Lohia P, Kapur S, Benjaram S, Cantor Z, Mahabadi N, Mir T, et al. Statins and clinical outcomes in hospitalized COVID-19 patients with and without diabetes mellitus: a retrospective cohort study with propensity score matching. Cardiovasc Diabetol. 2021;20(1):140.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01462-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01462-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T09:05:01Z","timestamp":1644829501000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01462-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01462-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1153818\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received an approval from Integreview\/Advarra Institutional Review Board (IRB) and all study participants were consented.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provide consent for publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors listed are employees of ObvioHealth. The first author is a principal investigator of this observational study who is responsible for the ObvioHealth study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}